A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-Positive Breast Tumor.

Next Previous
Trial Profile

A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-Positive Breast Tumor.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Docetaxel; Letrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms GETNA-2
  • Sponsors Sanofi

    • Most Recent Events

    • 03 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top